Paul is a scientist-entrepreneur with over two decades of experience turning discoveries into transformative life-science innovations. Trained in Bioengineering at UC Berkeley, he co-founded CellASIC, which commercialized the ONIX™ microfluidic live-cell imaging platform before being acquired by MilliporeSigma (Merck KGaA). At MilliporeSigma, Paul led post-acquisition integration and R&D operations before founding COMBiNATi, a digital PCR company and Endurance28 Fund I portfolio investment. COMBiNATi launched the Absolute Q™ digital PCR system and was acquired by Thermo Fisher Scientific in 2021.

After leading Thermo Fisher’s global digital PCR business through 2024, Paul joined Taudia—an Endurance28 Fund III portfolio company—as CEO, where he is advancing an ultrasensitive blood-based biomarker platform for Alzheimer’s disease and broader brain-health diagnostics.